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Circulating levels of glycine have previously been associated with lower incidence of coronary
heart disease (CHD) and type 2 diabetes (T2D) but it remains uncertain if glycine plays
an aetiological role. We present a meta-analysis of genome-wide association studies for
glycine in 80,003 participants and investigate the causality and potential mechanisms of the
association between glycine and cardio-metabolic diseases using genetic approaches. We
identify 27 genetic loci, of which 22 have not previously been reported for glycine. We show
that glycine is genetically associated with lower CHD risk and find that this may be partly
driven by blood pressure. Evidence for a genetic association of glycine with T2D is weaker,
but we find a strong inverse genetic effect of hyperinsulinaemia on glycine. Our findings
strengthen evidence for a protective effect of glycine on CHD and show that the glycine-T2D
association may be driven by a glycine-lowering effect of insulin resistance.
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C irculating levels of glycine, a non-essential amino acidinvolved in a wide range of metabolic pathways1, havebeen associated with lower incidence of myocardial
infarction (MI)2 and type 2 diabetes (T2D)3–6 in large-scale
epidemiological studies. A genetic study suggested a sex-specific
role of glycine metabolism on risk of coronary heart disease
(CHD)7, based on a genetic variant in carbamoyl-phosphate
synthase 1 (CPS1) which was associated with higher risk of CHD
in women but not in men. However, this study did not take into
account the stronger effect size of CPS1 on glycine in women8. A
recent Mendelian randomisation (MR) study suggested that low
glycine levels may be causally related to T2D risk, based on a
genetic score which was largely driven by CPS13. Due to pleio-
tropic effects of this locus, this association may have been driven
by glycine-independent mechanisms. Uncertainty about the role
of glycine metabolism on cardio-metabolic disease risk and its
potential sex-specific nature therefore remains.
Genome-wide association studies (GWAS) for plasma glycine
levels aiming to identify genetic regions involved in glycine
metabolism have been previously conducted in up to 25,000
participants, identifying five genetic loci associated with glycine
levels9–14. Potential sex differences in the effect sizes of these
loci have not been systematically assessed. A larger GWAS on
glycine could increase the number of genetic loci robustly asso-
ciated with glycine, thereby improving our understanding of the
genetic determinants of glycine metabolism and providing addi-
tional genetic instruments to assess the causality of glycine on
cardio-metabolic diseases and related risk factors, using the MR
framework15.
We here present a genetic discovery for glycine and identify 22
genetic loci which are novel for glycine. We construct and vali-
date sex-combined and sex-specific genetic scores for glycine with
different degrees of specificity to the glycine pathway. We find
that genetically predicted glycine is significantly associated with
CHD risk in men and women, which is in line with a causal role
for glycine and CHD risk, and identify blood pressure as a
potential mediator. We furthermore identify significant effects of
specific genetic variants in genes related to glycine catabolism on
T2D but evidence for an overall causal role of glycine levels
on T2D is weak. Genetically predicted insulin resistance (IR) is
strongly associated with lower glycine, which may drive the
consistently observed association between higher glycine levels
and lower incidence of T2D.
Results
22 novel genetic loci for glycine. We conducted a Z score-based
meta-analysis of GWAS for glycine levels in up to 80,003 parti-
cipants of European ancestry, including 55,673 participants from
the Fenland, INTERVAL and EPIC-Norfolk studies, and two
publicly available summary-level GWAS datasets (Supplementary
Table 1). 27 genetic loci were identified for glycine (p < 5 × 10−8),
of which 22 have not previously been reported for glycine (Fig. 1,
Supplementary Data 1). A total of 20 secondary signals at 8 loci
were identified through approximate conditional association
analyses (Supplementary Data 2). Six of the 27 loci are in (or
near) genes encoding enzymes involved in glycine metabolism
(Fig. 2). No evidence for heterogeneity between the studies was
found, except for the strongest locus, CPS1 (Supplementary
Data 1, Supplementary Figure 1).
Thirteen of the 27 glycine loci have been reported for cardio-
metabolic traits and risk factors, including blood lipid fractions16,
blood coagulation17–22 and glycaemic traits23, T2D24 and CHD25
(Supplementary Data 3). However, the direction of association
with the cardio-metabolic traits relative to the glycine-raising
allele was not consistent between loci, suggesting that these
pleiotropic loci do not reflect an overall shared genetic control of
glycine and cardio-metabolic traits.
Rs715 near CPS1 had by far the strongest effect on glycine
(per-allele beta ± standard error (SE) on standard deviations
(SDs) of glycine= 0.444 ± 0.006, effect allele frequency (EAF)=
31.3%) and explained 13.7% of the variance. This variant is in
high linkage disequilibrium (LD) (r2= 0.904) with a missense
variant (rs1047891). Conditioning on rs1047891 in EPIC-Norfolk
showed that the effect of rs715 was entirely driven by rs1047891
(beta ± SE for rs715 on glycine before adjustment = 0.565 ± 0.013;
after adjustment for rs1047891: beta= 0.032 ± 0.049).
Previous studies highlighted sex differences in the effect size of
the CPS1 locus on glycine8; we therefore assessed sex-specific effect
sizes of all 27 loci on glycine levels standardised by sex in the
Fenland, EPIC-Norfolk and INTERVAL studies (Bonferroni-
corrected p for sex difference based on 27 tests and two-sided
t-test: psex < 0.002). We confirmed that the effect of the CPS1 locus
on glycine is nearly three-fold stronger in women than in men
(women: beta ± SE= 0.691 ± 0.009, men: beta= 0.233 ± 0.007, p for
sex difference based on two-tailed t-test: psex < 2 × 10−302) and
found a similar sex difference in effect sizes on 65 other metabolites
significantly associated with rs715 in EPIC-Norfolk (Supplementary
Figure 2). Significant sex differences were also found for rs17591030
(GLDC, psex= 3.3 × 10−7) and rs10184004 (TRIB1, psex= 0.001)
(Fig. 3a, Supplementary Data 1). The cumulative variance in glycine
explained by the 27 variants was nearly 2.5 times higher in women
(25.1%) than in men (10.6%), which was mostly driven by the larger
effect size of rs715 in women (Fig. 3b).
Genetic scores for glycine: power versus specificity. The effect
size-weighted genetic score including all 24 common loci for
glycine explained 15.6% of the total variance in both sexes
combined, and 10.0% and 24.9% in men and women, respectively.
As a comparison, sex and BMI explained 8.6% and 3.4% of the
total variance in glycine levels, respectively, while other modifi-
able risk factors explained a very small proportion (alcohol
consumption: 0.51%, smoking: 0.08%) or none of the variance
(age and physical activity). The low-frequency (TUBGCP4) and
rare variants (FGG and KIF5B) were excluded from the genetic
score as look-ups for these were not available in all summary-level
GWAS datasets.
All 24 common loci were within 1Mb of or in LD with loci
previously reported for other metabolites (Supplementary Data 3).
We therefore tested to what extent the glycine score affected
metabolic pathways unrelated to glycine metabolism. Of the 894
metabolites available in EPIC-Norfolk, the 24 SNP score was
most strongly associated with glycine but also affected 73 other
metabolites (Bonferroni-corrected p for 894 tests based on two-
sided t-test: p < 5.6 × 10−5), of which the majority were strongly
correlated with and/or metabolically related to glycine (e.g., urea
cycle and choline metabolites, serine, glycine-conjugated fatty
acids). The 24 SNP score was also associated with several
metabolites with no known link to glycine, including phospho-
lipids and unknown metabolites (Supplementary Data 4).
We constructed three additional scores for glycine with
decreasing numbers of loci but increasing specificity to glycine
metabolism. The 6 SNP score was comprised of the six loci near
genes encoding enzymes related to glycine metabolism (Fig. 2),
explained 14.9% of the variance and remained associated with 70
metabolites (Supplementary Data 4). The CPS1 locus by itself was
significantly associated with all but seven of these 70 metabolites
(Supplementary Data 4). We therefore generated a third score that
excluded the pleiotropic CPS1 locus. This score explained 1.2% of
the glycine variance and was associated with 13 metabolites,
of which eight had a clear metabolic link to glycine
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(γ-glutamylglycine, N-acetylglycine, propionylglycine, N-palmi-
toylglycine, isovalerylglycine, serine and cinnamoylglycine) and
four were unknown metabolites. Finally, we constructed a 2 SNP
score, based on the loci at GCSH and GLDC encoding enzymes of
the glycine cleavage system, the major enzyme complex responsible
for glycine breakdown. The 2 SNP score explained 0.6% of the
variance in glycine and was associated with γ-glutamylglycine,
N-acetylglycine, propionylglycine, isovalerylglycine,
3-methylglutaconate and its carnitine conjugate, and one unknown
metabolite (Supplementary Data 4).
Glycine is genetically associated with lower CHD risk. Based on
MR analyses in up to 88,800 CHD cases and 485,266 controls and
using the 24 SNP score, we estimated that each SD higher
genetically predicted glycine was associated with an odds ratio
(OR) of 0.95 for CHD. ([95% confidence intervals (CI)]= [0.92,
0.98], p based on two-sided t-test: p= 0.001) (Fig. 4, Supple-
mentary Table 2). Sex-specific analyses in up to 9852 female and
21,994 male CHD cases showed that the effect sizes of glycine on
CHD risk were similar in women and men (p for sex difference


























Fig. 2 Schematic overview of glycine metabolism and six genetic loci for glycine in/near genes encoding enzymes related to glycine metabolism. GLDC
(glycine decarboxylase) and GCSH (glycine cleavage system protein H) are part of the glycine cleavage system, the major enzyme complex responsible for
glycine degradation. PHGDH (phosphoglycerate dehydrogenase) and PSPH (phosphoserine phosphatase) encode enzymes involved in the de novo
biosynthesis of serine, which can be converted into and synthesised from glycine. The interconversion of glycine and serine serves as an important source
of methyl groups in the folate cycle, a metabolic pathway of which the enzyme encoded by ALDH1L1 (aldehyde dehydrogenase 1 family member L1) is a
component. CPS1 (carbamoyl-phosphate synthase 1) encodes the enzyme responsible for the rate-limiting step of the urea cycle which is responsible for
the detoxification of ammonia. Glycine breakdown produces ammonia; changes in the efficiency of the urea cycle are therefore likely to have upstream


































































































































































































Fig. 1 Manhattan plot of Z score-based meta-analysis of GWAS for glycine levels. Loci in blue have not previously been reported for glycine. P-value for
CPS1 locus= 3 × 10−1632
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Figures 3 and 4). After taking into account the sex-specific effect
on glycine, the genetic glycine-CHD association based on CPS1
only did also not differ by sex (women: OR [95% CI]= 0.96
[0.91,1.00], men: OR [95% CI]= 0.94 [0.85,1.03], psex= 0.74).
Visual inspection of the scatter plots (Fig. 5), statistical tests for
heterogeneity and pleiotropy (Egger’s intercept p= 0.003; men-
only: Cochran’s Q p= 0.09) (Supplementary Table 2) and the
presence of several variants within the score associated with other
traits, suggest that the effect sizes of the 24 glycine-raising genetic
variants on CHD risk may be heterogeneous. To reduce the
influence of potential pleiotropic variants on the causal estimate,
we used the weighted median MR method for the main analyses.
To verify if the inverse association of genetically predicted glycine
with genetic risk of CHD was driven by glycine-unrelated
pathways, we conducted a series of sensitivity analyses using the


























































































































































































































































effect size on glycine (SD)
Fig. 3 Sex-specific effect sizes and cumulative variance explained by lead SNPs at the 27 genetic loci for glycine. a Sex-specific effect sizes of lead SNPs at
the significant loci for glycine levels based on a meta-analysis of the Fenland, EPIC-Norfolk and INTERVAL studies, including 30,226 men and 31,957
women. b Cumulative variance in glycine levels explained (r2) by lead SNPs at all 27 loci in men (N= 5086) and women (N= 5706) of the EPIC-Norfolk
study (sub-cohorts A and B)
OR for CHD per 1 SD genetically predicted or















Fig. 4 Forest plot of the odds ratios ± 95% confidence intervals for coronary heart disease per standard deviation observationally or genetically predicted
higher levels of glycine. Genetic estimates are based on 88,800 CHD cases and 485,266 controls. Sex-specific genetic analyses included 9,852 female
and 21,994 male CHD cases and 202,124 female and 164,944 male controls. For the sex-specific analyses, sex-specific standard deviations for glycine
were used, which were 0.321 and 0.195 (arbitrary units) for women and men in EPIC-Norfolk, respectively. Observational analyses are based on 11,147
participants (4989 men and 6158 women), of which 2053 (1223 men and 830 women) were incident CHD cases
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increasing specificity to glycine metabolism. When using the 6
SNP score which included loci with a known biological link to
glycine, similar effect estimates for glycine on CHD risk were found
and the heterogeneity decreased (Egger’s intercept p= 0.44; men-
only: Cochran’s Q p= 0.80) (Fig. 5b). Removing the strong but
pleiotropic CPS1 locus from the 6 SNP score increased the causal
effect estimate of glycine on CHD risk (sex-combined: OR= 0.80
[0.71,0.91], p= 4.8 × 10−4) (Fig. 5c), and a similar effect estimate
was obtained when using the 2 SNP score (GCSH and GLDC) (sex-
combined: OR= 0.80 [0.69,0.92], p= 1.7 × 10−3) (Fig. 5d, Supple-
mentary Table 2, Supplementary Figures 3 and 4). No significant
associations of genetically predicted glycine with stroke or with
stroke sub-types were found (Supplementary Figure 5, Supplemen-
tary Table 3).
In a non-genetic analysis using Cox proportional hazards
models adjusted for sex, glycine levels were associated with lower
risk of CHD and MI (CHD: hazard ratio (HR) for CHD per 1SD
higher glycine= 0.92, p based on two-sided t-test: p= 4.7 × 10−4;
MI: HR= 0.90, p= 0.005). This observational association was
similar to the genetically predicted association based on the 24
SNP score for glycine (Fig. 4). After adjustment for cardio-
metabolic risk factors, the associations of glycine were only
modestly (CHD) or not (MI) attenuated (CHD: HR= 0.95, p=
0.058; MI: HR= 0.90, p= 0.024). However, no association with
stroke was found (Supplementary Table 4).
Biological pathways mediating the effect of glycine on CHD.
To explore the biological mechanisms through which glycine
may influence risk of CHD, we investigated the downstream
effects of genetic differences in glycine levels on CHD risk factors,
including systolic (SBP) and diastolic blood pressure (DBP),
blood lipid fractions (triglycerides, HDL, LDL and total choles-
terol) and 13 potentially relevant blood cell traits (Bonferroni-
corrected p for 19 tests based on two-sided t-test: p < 2.6 × 10−3).
Genetically predicted glycine based on the 24 SNP score
was significantly associated with lower genetically predicted SBP
(beta ± SE per SD glycine on SD of SBP=−0.028 ± 0.007, p=
1.5 × 10−5) and nominally with lower genetically predicted DBP
(beta=−0.019 ± 0.009, p= 0.039). Similar effect sizes were found
for men and women separately (Fig. 6, Supplementary Table 5,
see Supplementary Figure 6 for sex-specific associations for
rs715). Effect estimates using the 6 SNP score were similar as
when using the 24 SNP score. When using the 5 and 2 SNP scores
for glycine, effect sizes tended to increase (Fig. 6, Supplementary
Table 5).
Glycine was not genetically associated with blood lipids and
blood cell traits. Associations with lower HDL cholesterol and five
blood cell traits reached significance when using the 24 SNP
score, but the effect sizes drastically decreased when using the 5
or 2 SNP scores, suggesting that the associations were driven by
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Fig. 5 Scatter plots of the effect sizes ± 95% confidence intervals of genetic variants for glycine on standard deviations of glycine levels versus the log odds
for coronary heart disease. a For the 24 SNP score, b 6 SNP score, c 5 SNP score and d the 2 SNP score. The orange line represents the slope estimated
using the weighted median method
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To test if the genetic association of glycine with CHD
was mediated through lowering blood pressure, we adjusted
the effect of genetically predicted glycine on CHD for genetically
predicted SBP and DBP. We used the 5 SNP glycine score
to reduce the likelihood of glycine-unrelated mechanisms.
Adjusting for SBP and DBP separately and together progressively
reduced the effect estimate of genetically predicted glycine
on CHD risk (Fig. 7). This suggests that the genetic association
of glycine with CHD risk may be mediated through blood
pressure.
The association of glycine with T2D may be pathway-specific.
Based on up to 74,124 T2D cases and 824,006 controls and the 24
SNP score, genetically predicted glycine was not associated with
T2D risk (OR [95% CI] for T2D per genetically predicted SD
higher glycine= 0.99 [0.96, 1.02], p for two-sided t-test: p= 0.59)
(Fig. 8, Supplementary Table 6). Sex-specific analyses in up to
12,013 female and 16,914 male T2D cases indicated that glycine
was also not genetically associated with T2D in men or women
only. Similar effect estimates were found across all 4 MR methods
and when using the 6 SNP score (Fig. 8, Supplementary Table 6).
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Fig. 6 Genetically predicted effect size ± 95% confidence intervals of glycine on diastolic and systolic blood pressure, in sex-combined and sex-specific
analyses, using four different genetic scores for glycine. Associations are based on 203,943 male and 241,417 female European ancestry UK biobank
participants
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Fig. 7 Forest plot of the odds ratios ± 95% confidence intervals for coronary heart disease per genetically predicted standard deviation of glycine, with and
without adjustment for blood pressure. CHD: coronary heart disease, DBP: diastolic blood pressure, SBP: systolic blood pressure, SD: standard deviation,
CI: confidence interval
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However, when using the 5 and 2 SNP scores which excluded
CPS1, the association of glycine with T2D reached significance
(Sex-combined OR based on 5 SNP score= 0.85 [0.76,0.96], p=
0.007; OR based on 2 SNP score= 0.82 [0.72,0.94], p= 0.004)
(Supplementary Figures 8-10, Supplementary Table 6). No evi-
dence for heterogeneity by sex was found (p for sex difference
based on two-sided t-test: 5 SNP score: psex= 0.88; 2 SNP score:
psex= 0.56). In an observational analysis, we replicated the strong
observational association of glycine levels with lower incidence of
T2D (HR [95% CI] for T2D per SD of glycine= 0.58 [0.47, 0.70]).
Hyperinsulinaemia as a driver of low glycine levels. To inves-
tigate if the association between low levels of glycine and high
incidence of T2D could be a consequence of early disease processes
of T2D, we assessed the genetically predicted effects of three T2D
risk factors—elevated body mass index (BMI), reduced early-phase
insulin secretion (IS) and IR—on levels of glycine. We found that
genetically higher IR was strongly associated with genetically lower
levels of glycine (beta [95%CI] on SDs of glycine levels per
genetically predicted unit of fasting insulin levels=−0.96 [−1.38,
−0.54], p based on two-sided t-test: p= 5.98 × 10−6), while
genetically predicted BMI (beta per SD genetically predicted BMI
on SDs of glycine levels=−0.04 [−0.10,0.02], p= 0.169) and IS
(beta per genetically predicted units of insulin at 30min during an
oral glucose tolerance test on SDs of glycine levels= 0.02 [−0.04,
0.09], p= 0.52) were not associated with glycine (Fig. 9). No evi-
dence for heterogeneity or directional pleiotropy was found for any
of the three traits. The inverse-variance weighted MR analyses were
therefore used as the main analyses, but similar effect sizes were
found using other MR methods (Supplementary Table 7).
Genetically higher glycine not linked to higher cancer risk. To
test whether higher levels of glycine may increase cancer risk, we







OR for T2D per genetically predicted SD of glycine
Fig. 8 Forest plot of the odds ratios ± 95% confidence intervals for type 2 diabetes per standard deviation genetically predicted higher levels of glycine
using four different genetic scores for glycine. Genetic estimates are based on 74,124 T2D cases and 824,006 controls for sex-combined analyses. Sex-
specific genetic analyses include 12,013 female and 16,914 male T2D cases and 202,124 female and 164,944 male controls. For the sex-specific analyses,
the standard deviations of the sex-specific glycine distributions were used, which were 0.321 and 0.195 (arbitrary units) for women and men in the EPIC-
Norfolk study, respectively. Results based on the weighted median MR method are shown
IR –0.96 [–1.38, –0.54]
0.021 [–0.04, 0.09]
Genetically predicted effect size on SDs of glycine
per unit difference in T2D risk factor
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Fig. 9 Forest plot of the genetic effect sizes ± 95% confidence intervals of insulin resistance (IR), early-phase insulin secretion (IS) and body mass index
(BMI) with glycine levels. Analyses were based on the inverse variance-weighted MR method
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OCAC27 and PRACTICAL28 GWAS consortia to assess asso-
ciations of genetically predicted glycine with risk of breast,
ovarian and prostate cancer. We found no evidence for an
increased risk for these three site-specific cancers for any of the
four genetic scores for glycine (Supplementary Table 8).
Discussion
Based on a genetic discovery in up to 80,003 participants from
five studies, we identify 22 loci not previously reported for gly-
cine. Two novel loci (PSPH and PHGDH) are located in genes
encoding enzymes catalysing the de novo biosynthesis of serine—
a pathway which has not previously been genetically associated
with glycine, despite the close metabolic link between glycine and
serine. We also identified two rare variants (in FGG and near
KIF5B) not previously reported for metabolic traits, which cor-
roborates previous evidence that rare genetic variation plays a
role in amino acid levels13.
Based on four genetic scores with different degrees of specifi-
city to the glycine pathway, we demonstrate that low levels of
glycine are genetically associated with higher risk of CHD, which
supports a potential protective role of glycine against CHD. The
effect size differs depending on the genetic score, with estimated
effects of glycine on CHD increasing with the degree of specificity
of the genetic score to glycine, which strengthens the evidence
that the observed genetic associations are driven by glycine. We
furthermore found that glycine has similarly protective effects in
men and in women, which contradicts findings by Hartiala et al.,7
who suggested that the sex-specific association of CPS1 with CHD
may reflect a causal role for glycine on CHD in women only. We
however show that, after taking into account the sex-specific
effect sizes on glycine, the genetic association of glycine with
CHD, based on CPS1 only and the four genetic scores for glycine,
is similar in magnitude in both sexes.
Our findings suggest that the inverse genetic association of
glycine with blood pressure may at least partly explain the genetic
glycine-CHD association. High blood pressure is a major risk
factor for cardiovascular diseases29 and glycine supplementation
has been shown to lower blood pressure in rodents30–32 and in
one small intervention study on human participants33. Our
findings corroborate a potential blood pressure-lowering effect of
glycine for the first time in a large-scale epidemiological setting. A
proposed mechanism through which glycine may lower blood
pressure is by the glycine-gated chloride channels expressed on
the endothelial surface, which upon binding of glycine induce
membrane hyperpolarisation and thus the production of nitric
oxide—a well-known vasodilator34. Despite the strong genetic
association of glycine with blood pressure, we cannot conclude
that the genetic effect of glycine on CHD risk is entirely mediated
through blood pressure, due to the limited power of the multi-
variable MR analyses. Moreover, the absence of associations
between glycine and stroke, for which hypertension is also a
major risk factor29, suggests that there also may be other phy-
siological pathways through which glycine influences cardiovas-
cular disease risk. We however find no evidence for a role of
glycine in lipid metabolism or blood cell traits, despite previous
studies suggesting that glycine may regulate lipid metabolism2
and platelet35 and immune cell activation36. There may be other
mechanisms underlying the genetic glycine-CHD association
which we could not investigate here. For example, glycine may
protect against oxidative stress, as it is a substrate for the
biosynthesis of glutathione—a major antioxidant in human
cells37,38.
While multiple observational epidemiological studies have
linked high glycine levels to lower incidence of T2D3,4,39, the
genetic evidence for causality is weaker. MR analyses based on the
larger but less specific genetic scores indicate no causal effect of
glycine on risk of T2D, while variants in genes related to glycine
catabolism drive associations of the 5 and 2 SNP scores with
lower T2D risk. These findings suggest that overall levels of
glycine may not be causal for T2D but that low glycine levels due
to changes in the catalytic efficiency of the glycine cleavage sys-
tem—the protein complex that catalyses the major catabolic
pathway of glycine40—may cause higher risk of T2D. Coding
mutations in genes of the glycine cleavage system have been
identified as one of the causes of severe hyperglycinemia41, a life-
threatening inborn error of metabolism, and have been linked to
higher risk of neural tube defects42. To the best of our knowledge,
this enzyme complex has not previously been linked to common
cardio-metabolic diseases. An alternative interpretation of our
findings is that overall glycine levels are causally associated with
T2D risk, but that this association is masked by pleiotropic effects
of CPS1. As CPS1 had a 10-fold stronger effect on glycine than
most other glycine-associated variants, the genetic scores which
included CPS1 in fact mostly represented CPS1. The CPS1 locus
has widespread effects across the metabolome, which are not
restricted to the glycine pathway, and has also been associated
with other traits, of which some, including glycine, may protect
against T2D while others could increase T2D risk. Therefore, the
null-association based on the genetic scores including CPS1 may
have been driven by glycine-independent pathways and may thus
mask a true genetic association of glycine with T2D.
Our findings do not entirely replicate the recently reported
protective effect of glycine on T2D based on an MR analysis using
five loci for glycine3. The significant inverse genetic association of
glycine with T2D risk reported by Merino et al. was largely driven
by CPS1, of which the glycine-raising allele was nominally asso-
ciated with lower T2D risk in the 11,600 T2D cases and 33,000
controls. Our analyses based on 74,124 T2D cases and 824,006
controls did not replicate the nominal association with T2D for
CPS1, nor for the genetic scores that included CPS1.
We find strong genetic evidence that low glycine levels are a
consequence of IR, which suggests that the inverse association of
glycine levels with incidence of T2D is at least partly driven by IR.
Observational epidemiological research has previously described
that measures of IR are inversely associated with glycine43,44 and
rodent experiments suggest that increased oxidative stress caused
by IR leads to a higher rate of glutathione synthesis, which may
lead to glycine depletion45. Another proposed mechanism that
could link IR to lower levels of glycine is the increased demand
for glycine to safely excrete fatty acyl-CoA esters which accu-
mulate as a consequence of incomplete suppression of lipolysis
and resulting high circulating levels of fatty acids in the insulin
resistant state46. Free fatty acids can lead to a build-up of beta
oxidation intermediates, i.e., fatty acyl-CoA esters, which can
upon trans-conjugation with glycine be safely excreted as fatty
acyl-glycine46,47.
Our findings raise the question whether glycine supplementa-
tion merits evaluation as a strategy to prevent cardio-metabolic
disease. A variety of glycine supplements are available for pur-
chase “over the counter” and are used without clinical follow-up
for a wide range of indications. To consider the preventive value,
the potential benefits and harms should be assessed. Effect sizes
for CHD varied depending on the “specificity” of the genetic
score and, in addition, CI across these estimates varied, ranging
from 0.69 to 0.98 per SD higher glycine levels. However, the
increase in the effect estimate of glycine with increasing specificity
of the genetic score suggests that the benefit may be considerable.
This, together with the feasibility of achieving the required glycine
concentration in blood given its short half-life48, and any
potential harms arising, require piloting under controlled con-
ditions. In terms of safety, in vitro and animal-based evidence has
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suggested that glycine and serine may promote oncogenesis by
fuelling one-carbon and folate metabolism49. This is indirectly
supported by a suggestive association between folic acid supple-
mentation and cancer incidence50. Furthermore, it was recently
shown that a serine and glycine-depleted diet improves treatment
response and survival in murine models of colorectal cancer and
lymphoma51. Our genetic analyses of three site-specific cancers
where GWAS summary statistics were available to provide
maximum power and specificity did not provide evidence that
glycine levels increase the risk of breast, ovarian or prostate
cancer. However, consortia data for other cancer sites and types
are required to provide genetic evidence against an increased risk
for site-specific cancers other than breast, ovarian and prostate,
and a thorough assessment of the potential carcinogenicity of
glycine is required before glycine supplementation can be con-
sidered even in an evaluative setting in human participants.
Our investigation into the aetiological role of glycine metabo-
lism in cardio-metabolic diseases has several strengths. The var-
iance in glycine levels explained by the genetic score comprising
24 loci was more than 15%, which enabled us to conduct well-
powered MR experiments. The high proportion of explained
variance can be attributed to the biological specificity of the
exposure. Secondly, we conducted a thorough assessment of
pleiotropic effects of the genetic scores for glycine and generated
a series of subsets of the full genetic score with increasing spe-
cificity to glycine metabolism, in order to reduce the likelihood of
contributions of glycine-unrelated metabolic pathways to the
causal effect estimate. We adopted multiple MR approaches,
including robust methods which are less sensitive to bias due to
pleiotropic effects by a subset of genetic variants within the
score52–54, which further decreases the chance that the genetically
determined effect estimate was driven by glycine-independent
pathways.
We are aware of certain limitations to our study. First, due to
differences in imputation reference panels between the studies
included in the GWAS for glycine, sample sizes differed between
the tested variants. Therefore certain loci, in particular those only
covered in UK10K and rare variants, which have been shown to
influence amino acid levels13, may not have reached significance.
Secondly, some of the studies upon which our analyses were
based were enriched for healthy participants, e.g., UK Biobank55
and INTERVAL. It has recently been suggested that selection bias
could theoretically lead to a false positive genetic association
between an exposure and an outcome if both the exposure and
the outcome influence the likelihood of an individual partici-
pating in the study56. As individuals are not aware of their glycine
levels, any such selection would have to be indirect through other
factors that affect glycine and bias participation in each of the
independent studies included in the same direction. We therefore
consider the extent to which collider bias could be influencing the
MR results due to a healthy participant effect to be small. Finally,
despite undertaking sensitivity analyses, we cannot exclude the
possibility that our findings may be driven by vertical pleiotropic
effects of the genetic instruments. As the metabolome is com-
prised of thousands of metabolites connected through numerous
reactions, some of which may be unknown, the distinction
between horizontal and vertical pleiotropy is difficult to make in
the context of metabolomics. The 2 SNP score, comprised of loci
in genes of major enzymes of glycine catabolism, is the most
specific score to the glycine pathway but still shows modest
associations with some metabolites of which we cannot be sure
that they are metabolically linked to glycine, e.g., the unknown
metabolite X-16570, and with glycine-conjugated metabolites,
which may have effects independent of glycine on cardio-
metabolic disease risk. Therefore, we cannot fully exclude that
glycine-independent mechanisms may have biased the genetically
predicted association of glycine with disease risk. Moreover, as
glycine is a metabolite on the intersection of many metabolic
pathways, the genetic association of glycine with cardio-metabolic
diseases may represent the causal effect of a metabolite to which
glycine is metabolically close linked (e.g., tetrahydrofolate or
serine).
In conclusion, we show that low glycine is associated with
higher incidence of CHD and that genetic scores for glycine are
compatible with this relationship being causal. We furthermore
show that a glycine-lowering effect of IR may drive the con-
sistently reported association between higher glycine and lower
incidence of T2D, while the evidence for a causal relationship
between glycine and T2D risk is weaker.
Methods
Studies. The EPIC-Norfolk study is a cohort of 25,000 individuals aged between 45
and 74 from the general population of Norfolk (East England)57, nested within the
European Prospective Investigation into Cancer and Nutrition (EPIC). The study
was approved by the Norfolk Research Ethics Committee (ref. 05/Q0101/191) and
all participants gave their written consent before entering the study. Untargeted
metabolomics measurements using the DiscoveryHD4® platform58 (Metabolon,
Inc., Durham, USA) on non-fasted plasma samples have been completed in a T2D
case-cohort study which included all 586 incident T2D cases and 746 quasi ran-
domly selected participants from the entire cohort, and two sub-cohorts of quasi
randomly selected participants—5989 participants in sub-cohort A and 5977
participants in sub-cohort B. There was no overlap between the T2D case-cohort
and sub-cohorts A and B. Further details about the metabolomics measurements
and QC have previously been described elsewhere59. Genome-wide genotyping was
done using the Affymetrix UK Biobank Axiom array and genotype data were
imputed to the 1000 Genomes Phase 3 reference panel60 using IMPUTE261. Data
from EPIC-Norfolk were used to conduct a GWAS for glycine (sub-cohort of the
T2D case-cohort and sub-cohort A), to estimate sex-specific effect sizes of the
lead SNPs for glycine on glycine levels (sub-cohort A and B), to test associations of
the genetic scores and variants for glycine across the metabolome (sub-cohorts A
and B), and to assess the observational association of glycine levels with incident
CHD, MI, stroke (sub-cohorts A and B) and T2D (T2D case-cohort).
EPIC-CVD, another sub-study of EPIC, is a prospective case-cohort study
focussing on the risk factors of cardiovascular diseases and includes nearly 14,000
incident CHD cases and a sub-cohort comprised of 18,249 randomly selected
participants62. Ethical approval was obtained from the ethics committees of the
International Agency for Research on Cancer and the local institutions where the
participants were recruited. Genotyping was performed using the
HumanCoreExome array, the Quad 660 array and the Infinium
OmniExpressExome array (all from Illumina) and genotyped data were imputed
based on the Haplotype Reference Consortium reference panel. Data on 28,217
participants (33.7% CHD cases) of the EPIC-CVD study were used to assess the
effect sizes of the genetic variants for glycine with CHD, for both sexes combined
and separately.
InterAct is a T2D case-cohort study nested within EPIC, which was designed to
study the interaction between lifestyle and genetic factors in relation to T2D63. All
participants gave written informed consent and ethical approval was given by the
ethics committees of the International Agency for Research on Cancer and the local
institutions. The study includes 12,403 incident cases of T2D and a randomly
selected sub-cohort of 16,154 individuals from nine European countries. Genome-
wide genotyping was done using the HumanCoreExome array. Genome-wide
genotyped data were imputed to the European 1000 Genomes reference panel
(March, 2012 release) using IMPUTE2. Data from the InterAct study were used to
assess the sex-specific associations of the genetic loci for glycine with risk of T2D.
The Fenland study is a longitudinal cohort study including more than 12,400
participants born between 1950 and 1975 from the general population of
Cambridgeshire (UK)59. Ethical approval for the study was was given by the
Cambridge Local Ethics committee (ref. 04/Q0108/19) and all participants gave
their written consent prior to entering the study. Fasted plasma concentrations
of 174 metabolites were measured using the AbsoluteIDQ® p180 Kit (Biocrates Life
Sciences, Innsbruck, Austria). Further details about the metabolomics
measurements and QC have previously been described elsewhere59. Genome-wide
genotyping of the Fenland participants was done in two waves; the first 1400
individuals were genotyped using the Affymetrix Genome-Wide Human SNP
Array 5.0 and the next 9369 participants on the Affymetrix UK Biobank Axiom
Array. The same imputation strategy as for the EPIC-Norfolk study was used.
GWAS for glycine and assessment of the sex-specific effect sizes of the glycine
variants were run in the Fenland study.
The INTERVAL study is a randomised trial of ~50,000 whole blood donors
enrolled from all 25 static centres of NHS Blood and Transplant64. All participants
gave written informed consent and the study was approved by NRES Committee
East of England - Cambridge East (ref. 11/EE/0538). For the present study, non-
fasting serum blood samples were provided by unrelated individuals from the
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-08936-1 ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:1060 | https://doi.org/10.1038/s41467-019-08936-1 | www.nature.com/naturecommunications 9
INTERVAL trial. The samples were analysed using a high-throughput serum NMR
metabolomics platform65,66, which provided information on 230 metabolites,
including glycine. We removed participants with >30% of metabolite measures
missing, duplicated individuals, and metabolic data more than 10 SDs from the
mean. Genotyping was conducted using the Affymetrix UK Biobank Axiom array.
Prior to imputation, SNPs missing in more than 1% of the samples or failing in
more than one batch were excluded. Monomorphic and multi-allelic variants and
variants that failed to pass the threshold on clustering quality, were intensity
outliers or deviated from Hardy-Weinberg equilibrium were omitted. The data
were imputed to a joint 1000 Genomes Phase 3 (May 2013)-UK10K reference
imputation panel. Data from 40,509 INTERVAL participants with glycine
measures were used to run a GWAS for glycine and to assess the sex-specific effect
sizes of the glycine variants on glycine.
The UK Biobank study is a longitudinal cohort study of more than 500,000
participants from across the UK67. All participants gave their informed consent.
Genotyping was performed using the UK Biobank Axiom Array and imputation
was based on the reference panel from the Haplotype Reference Consortium, using
IMPUTE2. Associations of the genetic variants for glycine with CHD, T2D and
blood pressure were assessed in the UK Biobank.
Genome-wide association analyses for glycine. GWAS for glycine levels were
conducted in the Fenland (n= 9324), EPIC-Norfolk (n= 5840) and INTERVAL
(n= 40,509) studies. Glycine levels were natural log transformed, winsorised at
5 SDs and transformed to the Z score. Analyses were conducted based on a
generalised linear mixed model adjusted for age, sex and the first four principal
components, using BOLT-LMM68. For the Fenland study, separate GWAS were
run for the two different genotyping arrays, which were meta-analysed using a
fixed-effects model in METAL68. The GWAS in EPIC-Norfolk only included the
sub-cohort of the T2D case-cohort study and sub-cohort A, as at the time the
GWAS was conducted, metabolite measurements in sub-cohort B were not yet
available. For the GWAS in EPIC-Norfolk, batch (i.e., sub-cohort of T2D case-
cohort or sub-cohort A) was included as an additional covariate. Genetic variants
were excluded if the standard error (SE) > 10 or <0, the absolute value of beta >5, p
for the Hardy-Weinberg equilibrium <1 × 10−6 or info score <0.4 (INTERVAL) or
<0.3 (Fenland and EPIC-Norfolk).
Meta-analyses of GWAS for glycine. Results of the Fenland, EPIC-Norfolk and
INTERVAL studies were meta-analysed with publicly available summary-level
GWAS results from an NMR-based multi-cohort discovery by Kettunen et al.11
(downloaded from http://www.computationalmedicine.fi/data#NMR_GWAS) and
from TwinsUK published by Shin et al.69 (downloaded from http://mips.
helmholtz-muenchen.de/proj/GWAS/gwas/index.php?task=download), resulting
in a total sample size of up to 80,003 individuals. Meta-analysis of the five studies
was conducted using METAL70 and was based on the p-values, directions of effect
and sample sizes, to minimize the effect of heterogeneity due to differences between
metabolomics platforms and in analytical decisions between the studies, such as
transformation of the glycine measures and inclusion of covariates (Supplementary
Table 1). As the five studies differed in terms of adopted imputation strategy,
analyses were restricted to variants covered in at least two studies and >50% of
the total sample size, and with MAF ≥0.1%. Pooled effect sizes and SEs were
generated through an effect size-based meta-analysis of the Fenland, EPIC-Norfolk
(sub-cohort of T2D case-cohort and sub-cohort A) and INTERVAL studies
(total n= 55,673) in METAL.
Identification of primary and secondary genetic signals. Distance-based
clumping using 1Mb windows was used to identify independent loci significantly
associated with glycine (p < 5 × 10−8). Because of the very strong and wide signal at
CPS1, a window of 3Mb on both sides of the lead variant rs715 was used to capture
the entire locus. Secondary signals were identified through approximate conditional
analyses using GCTA-COJO71. To maximise the sample size, this analysis was
conducted on the pooled Z scores generated in the p-value-based meta-GWAS.
Variants with MAF < 1% were omitted from the conditional analyses. HRC-
imputed genome-wide data from 19,318 EPIC-Norfolk participants were used as an
LD reference panel and a joint p-value threshold of 5 × 10−8 was used to identify
secondary signals. Of the 73 variants selected through the approximate conditional
analysis, 11 were in LD (r2 > 0.05) with another selected variant and were therefore
omitted. At the CPS1 locus, 44 secondary signals remained of which 27 were low-
frequency variants. A second LD filter to remove variants in high LD with the
common sentinel variant (D’ < 0.05) was applied, after which only five variants
at the CPS1 locus remained.
Sex-specific effect sizes of glycine loci. Sex-specific effect sizes for lead SNPs at
the 27 loci on glycine levels standardised by sex were estimated in the INTERVAL,
Fenland and EPIC-Norfolk studies (sub-cohorts A and B) (in total 30,226 men and
31,957 women) and meta-analysed using the R package ‘metafor’72. As a sensitivity
analysis, sex-specific effect sizes on natural-log transformed instead of within-sex
standardised glycine levels were estimated in the Fenland and EPIC-Norfolk
studies (9927 men and 11,284 women).
Annotation of lead SNPs and genetic scores for glycine. Lead variants at the
27 loci identified for glycine levels were annotated using ANNOVAR73 and we
searched for published associations for all lead variants and variants in high LD
(r2 > 0.6) using the PhenoScanner web browser74. Reported associations with
metabolites were identified using SNiPA for the lead variants and variants within
1 Mb of or in high LD (r2 > 0.8) with the lead variants75.
Associations of the four different glycine scores and rs715 at CPS1 with 894
metabolites measured in sub-cohorts A and B and at least 50% of the total sample
size of the EPIC-Norfolk study were assessed. Metabolite levels were natural log-
transformed and transformed to the Z scores and models were adjusted for sex and
metabolite batch.
Associations of glycine lead SNPs with diseases and traits. Sex-combined and
sex-specific effect estimates of the lead variants for glycine (or a variant in high
LD (r2 > 0.7) if the lead variant was not available) on CHD were assessed in the
EPIC-CVD study and the UK Biobank, and obtained as lookups from CARDIo-
GRAMplusC4D25 for the sex-combined associations (60,801 cases and 123,504
controls, downloaded from http://www.cardiogramplusc4d.org/data-downloads/)
and from the German MI family studies25,76–78 for sex-specific associations
(994 female and 2804 male cases; 2752 female and 2554 male controls). The
associations of the genetic variants for glycine with CHD were tested in EPIC-CVD
based on Cox proportional hazards models and using Prentice weighting and
robust standard errors (3712 female and 5786 male cases; 14,764 female and 13,453
male controls). Models were adjusted for age, genotyping array, testing centre, the
first four genetic PCs and sex for the sex-combined analyses. In the UK Biobank,
Cox proportional hazards models adjusted for age, the first 10 PCs, genotyping
chip and sex (for sex-combined analyses) were run on 18,501 incident and pre-
valent CHD cases (5147 women) and 333,545 controls (184,608 women).
Associations of the glycine SNPs with any stroke and ischemic stroke were
based on look-ups in the summary-level GWAS results from the MEGASTROKE
consortium79 (downloaded from http://www.megastroke.org/download.html) and
associations in the UK Biobank (Any stroke: up to 48,916 cases and 765,017 non-
cases; ischemic stroke: up to 37,771 cases and 764,290 non-cases). Associations
with haemorrhagic stroke were based on data from UK Biobank only (1655 cases
and 365,988 non-cases). Stroke and stroke sub-type cases in UK Biobank were
identified based on ICD-9 and ICD-10 codes, cause of death (based on ICD-10
codes) and on self-reported diagnoses based on a verbal interview.
Associations of the glycine variants with T2D for sexes combined were obtained
from the latest GWAS on T2D by the DIAGRAM consortium on 74,124 cases and
824,006 controls80 (downloaded from http://www.diagram-consortium.org/
downloads.html). Sex-specific associations with T2D were based on the InterAct
(4712 female and 4596 male cases; 7190 female and 4333 male controls) and UK
Biobank studies (7301 female and 12,318 male cases; 181,442 female and 149,249
male controls). Sex-specific GWAS for T2D in the InterAct study were run using
SNPTEST, based on logistic regression models adjusted for age, assessment centre
and the first 10 genetic PCs. In the UK Biobank, associations of the SNP dosages
with prevalent and incident T2D, identified based on ICD10 codes, were estimated
by fitting logistic regression models adjusted for age, four genetic PCs and
genotyping chip in STATA v15.0 (StataCorp, College Station, Texas, USA). Only
UK Biobank participants from the subset of unrelated British ancestry participants
were included. Meta-analyses of the sex-specific effect sizes were meta-analysed
using the R package ‘metafor’72.
The effects of the glycine variants on SBP and DBP were assessed using data on
445,360 UK Biobank participants (241,417 women) of European ancestry. GWAS
on rank-based inverse normally transformed SBP and DBP were conducted within
sex and using BOLT-LMM. For individuals who reported to be taking
antihypertensive medication, 15 mmHg and 10 mmHg was added to measured SBP
and DBP81. Analyses were adjusted for age, age2, BMI and genotyping array.
For variants both genotyped and imputed, imputed probabilities were used if
the variant was imputed well (INFO > 0.7) and the genotyping call rate was less
than 98%. Sex-combined estimates were generated through fixed-effect meta-
analyses of the sex-specific estimates.
Associations of the glycine variants with triglycerides, LDL, HDL and total
cholesterol were obtained from publicly available GWAS summary-results based
on up to 188,577 participants from the Global Lipids Genetics Consortium16
(downloaded from http: //csg.sph.umich.edu/abecasis/public/lipids2013/). Look-
ups for 13 blood cell traits came from publicly available GWAS summary
results based on a genetic discovery in 173,480 participants82 (downloaded from
http://www.bloodcellgenetics.org/).
Look-ups for overall breast cancer risk were obtained from a European ancestry
genetic discovery for breast cancer including up to 122,977 cases and 105,974
controls26 (downloaded from http://bcac.ccge.medschl.cam.ac.uk/bcacdata/
oncoarray/gwas-icogs-and-oncoarray-summary-results/). Genetic associations with
epithelial ovarian cancer were obtained from publicly available results of a genetic
discovery including 25,509 cases and 40,941 controls of European ancestry from
OCAC27 (downloaded from http://ocac.ccge.medschl.cam.ac.uk/data-projects/
results-lookup-by-region/). Look-ups for prostate cancer came from the publicly
available summary-level results of a GWAS including 79,148 prostate cancer cases
and 61,106 controls of European ancestry (downloaded from: http://practical.icr.ac.
uk/blog/?page_id=8164).
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MR methods. MR analyses for glycine to cardio-metabolic diseases and
cancers were based on summary-level data and four different methods: inverse
variance-weighted MR83, MR-Egger53, weighted median MR and penalised
weighted median MR52. Heterogeneity in the effects of the genetic variants on
the outcome was assessed based on the Cochran’s Q statistic, and directional
pleiotropy was estimated based on the MR-Egger intercept. The weighted median
MR was used for the main analyses, as across the analyses and phenotypes,
there was proof of heterogeneity (p for Cochran’s Q < 0.05 and/or p for Egger’s
intercept < 0.05).
Two-sample summary-level data multivariable MR analyses to obtain the effect
size of glycine levels adjusted for blood pressure on CHD were run as previously
described by Day et al.84. In brief, weighted multilinear models were fitted with
the effect sizes of the glycine SNPs on glycine and on the SBP and/or DBP as the
explanatory variables and the effect sizes of the glycine SNPs on CHD as the
independent variable. Weighting was based on the inverse variance of the effect
sizes of the genetic variants for glycine on CHD.
Reverse MR analyses were conducted to assess the causality of risk factors for
T2D on glycine levels using the same analytical approach as for the forward MR
analyses. Previously published and validated genetic scores by the GIANT and
MAGIC consortia were used for BMI85 (97 genetic variants), fasting insulin
adjusted for BMI as a marker of IR86 (10 genetic variants) and insulin levels at
30 min during an oral glucose tolerance test as a marker for early-phase IS86,87
(21 genetic variants). As there was no evidence for heterogeneity or pleiotropy,
the inverse variance-weighted MR method was used.
Observational analyses. We tested if glycine levels at baseline were associated
with incidence of CHD, MI and stroke in the EPIC-Norfolk study. Analyses for
CHD, MI and stroke were performed in sub-cohorts A and B, while analyses for
T2D were conducted in the T2D case-cohort study (586 incident cases and 746
quasi randomly selected participants). During follow-up, 2053 participants devel-
oped CHD, of which 659 participants had MI. In total, 1163 participants had a
stroke, of which 212 cases were confirmed to be haemorrhagic and 569 were
confirmed to be ischemic. Cox proportional hazards models were fitted to estimate
the HRs for disease incidence based on 1 SD increase in glycine levels. Age at
recruitment was used as the underlying timescale, and models were adjusted for
sex, and additionally for BMI, waist-hip ratio, educational attainment, smoking,
alcohol consumption, physical activity, blood pressure and blood lipids in the fully
adjusted models. Prevalent disease cases were excluded from the analyses. Prentice
weighting was applied to the models for T2D, to adjust for the enrichment of cases.
Analyses for CHD, stroke and MI were conducted for the sub-cohorts separately
and meta-analysed using metafor72. Sex-specific analyses were conducted on
within-sex standardised glycine levels.
The association of glycine levels with sex, age, smoking (number of cigarettes/
day), alcohol consumption (grams of alcohol/day) and physical activity (energy
expenditure from physical activity/day) was tested based on a linear regression
model adjusted for metabolomics batch and included 10,475 participants (5612
women) of the Fenland study.
Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The summary statistics of the meta-GWAS for glycine levels are available as
Supplementary Data 5. All other data are contained within the article and its
supplementary information, or can be obtained upon reasonable request from the
corresponding author.
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